Grifols completes patient follow-up in phase 3 alpha-1 lung study
Tweet Send to a Friend
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) announced the completion of patient follow-up in SPARTA, its phase 3 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
